Isolagen, Inc. to Present at the First Albany Capital Regenerative Technologies Conference
September 05 2007 - 9:00AM
PR Newswire (US)
EXTON, Pa., Sept. 5 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc.
(AMEX:ILE) today announced that Nicholas L. Teti, Jr., Isolagen
Chairman and Chief Executive Officer, will present at the First
Albany Capital Regenerative Technologies Conference on Tuesday,
September 11, 2007 at 10:20 a.m. ET. The conference will be held at
The Yale Club of New York in New York City. The presentation can be
accessed by visiting the investor relations section of the
Company's website at http://www.isolagen.com/. About Isolagen, Inc.
Isolagen(TM), Inc. (AMEX:ILE) is an aesthetic and therapeutic
company committed to developing and commercializing scientific
advances and innovative technologies. The company's technology
platform includes the Isolagen Process(TM), a cell processing
system for skin and tissue rejuvenation which is currently in
clinical development for a broad range of aesthetic and therapeutic
applications including wrinkles, acne scars, burns and periodontal
disease. Isolagen also commercializes a scientifically-advanced
line of skincare systems through its majority-owned subsidiary,
Agera(R) Laboratories, Inc. For additional information, please
visit http://www.isolagen.com/. Isolagen Forward Looking Statements
All statements in this news release that are not based on
historical fact are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995 and the
provisions of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. While management has based any forward-looking statements
contained herein on its current expectations, the information on
which such expectations were based may change. These
forward-looking statements rely on a number of assumptions
concerning future events and are subject to a number of risks,
uncertainties, and other factors, many of which are outside of our
control, that could cause actual results to materially differ from
such statements. Such risks, uncertainties, and other factors
include, but are not necessarily limited to, those set forth under
Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K
for the year ended December 31, 2006, as updated in "Item 1A. Risk
Factors" in the Company's Quarterly Reports on Form 10-Q. We
operate in a highly competitive and rapidly changing environment,
thus new or unforeseen risks may arise. Accordingly, investors
should not place any reliance on forward-looking statements as a
prediction of actual results. We disclaim any intention to, and
undertake no obligation to, update or revise any forward-looking
statements. Readers are also urged to carefully review and consider
the other various disclosures in the Company's Annual Report on
Form 10-K for the year ended December 31, 2006, as well as other
public filings with the SEC since such date. DATASOURCE:
Isolagen(TM), Inc. CONTACT: Media, Mike Beyer of Sam Brown Inc.,
+1-773-463-4211, , for Isolagen(TM), Inc., or, Investors, Charles
Huiner of Isolagen, +1-484-713-6200, Web site:
http://www.isolagen.com/
Copyright
Isolagen (AMEX:ILE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Isolagen (AMEX:ILE)
Historical Stock Chart
From Jul 2023 to Jul 2024